Professional
Added to YB: 2025-01-03
Pitch date: 2024-12-20
IONS [bullish]
Ionis Pharmaceuticals, Inc.
+130.64%
current return
Author Info
No bio for this author
Company Info
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.
Market Cap
$13.2B
Pitch Price
$36.05
Price Target
69.00 (-17%)
Dividend
N/A
EV/EBITDA
-54.60
P/E
-50.43
EV/Sales
13.44
Sector
Biotechnology
Category
growth
Ionis Pharmaceuticals, Inc.: FDA Approves Rare-Disease Drug Tryngolza; Shares Undervalued for Long-Term Investors
IONS: FDA approves Tryngolza for FCS. $69 price target, 5-star undervalued. First independent launch, 3000 US patients. ASO leader, strong pipeline. Competition from Arrowhead's plozasiran. Wainua launching 2024, $3B+ potential. Olezarsen, donidalorsen in 2025. Multiple readouts through 2025. Risks: unprofitability, competition, partnering limits.
Read full article (9 min)